Clinical Trials 2010 - Invest up to 50% less and be among the experts from the industry

North West Business Group29 - 30 September 2010, Frankfurt, Germany.
In the current environment where minimising cost and delivering ROI are critical themes within the pharma industry, improving your clinical trial infrastructure can ensure that time is not wasted and you are maximising your investments. Attend Clinical trials 2010, this two day meeting which is concise and packed with value, Presentations that will be case-study oriented, supplemented by panel discussions and network with leading practitioners to provide information to keep clinical trials goal-oriented, on-time and cost-effective. Take-aways will include presentations with information that can readily be adapted to clinical trial projects in your organization.The 2010 event is set to be a highlight in the clinical trial events calendar. What's more, it is widely accepted that there is nothing better than to learn from the experience of experts rather than trying to build that knowledge yourself.

The programme covers a wide range of topics including:

  • Clinical Trials in the 21st Century
  • Clinical trials in emerging economies: myth and reality
  • How to optimize the global patient recruitment process
  • Working with Academic Study Groups
  • How to attract and retain clinical trials in western countries
  • Outsourcing Innovative approaches
  • The effect of EU regulations on conducting clinical trials
  • Joins some of the experts like:
  • Astrazeneca, Clinical Research Director Europe
  • Grunenthal, Head of Clinical Operations
  • MDC, Senior PartnerProduct Specialist Clinical Business Intelligence Systems
  • Novartis, Chief Scientific Officer
  • Glaxo Smith Kline, Director Clinical Research
  • Actelion, Director, Global Clinical Development Affairs
  • Novartis, Head Clinical Operations
  • Lundbeck, Senior Specialist, Outsourcing
  • Janssen-Cilag, Head Clinical Trials
  • Sanofi-Aventis, Head of Clinical Research Unit
  • Bayer Health care, EDC Director
  • Pfizer, Associate Director Worldwide Regulatory Affairs & Quality Assurance
  • And many more...

Who should attend?
This conference is designed to attract key decision makers from the Pharmaceutical industry: Presidents, Managing Directors, Country Managers, General Managers, Vice Presidents, Regional Directors/ Heads, Directors, Department Heads, Managers.

For further information and registration, please visit:
http://nwbg.eu/all-events/clinical-trials-2010/

Most Popular Now

Fasenra (benralizumab) receives US FDA approval fo…

AstraZeneca and its global biologics research and development arm, MedImmune, announced that the US Food and Drug Administration (FDA) has approved Fasenra (benralizumab)...

A great place to do great things: Developing game-…

Science has spoken: Abbott (NYSE: ABT) is, again, among the best science-based companies to work for in the world. For the 14th year, the journal Science today recognized...

Alzheimer's disease might be a 'whole body' proble…

Alzheimer's disease, the leading cause of dementia, has long been assumed to originate in the brain. But research from the University of British Columbia and Chinese scie...

Cancer cells destroyed with dinosaur extinction me…

Cancer cells can be targeted and destroyed with the metal from the asteroid that caused the extinction of the dinosaurs, according to new research by an international col...

Novartis confirms leadership in multiple sclerosis…

Novartis today announced it will present 54 scientific abstracts from across its multiple sclerosis (MS) research portfolio at the 7th Joint European and Americas Committ...

Amgen and Novartis announce expanded collaboration…

Amgen (NASDAQ:AMGN) and Novartis announced an expanded collaboration with the Banner Alzheimer's Institute (BAI) to initiate a new trial - the Alzheimer's Prevention Init...

Transplanted hematopoietic stem cells reverse dama…

Researchers at University of California San Diego School of Medicine report that a single infusion of wildtype hematopoietic stem and progenitor cells (HSPCs) into a mous...

Scientists find where HIV 'hides' to evade detecti…

In a decades-long game of hide and seek, scientists from Sydney's Westmead Institute for Medical Research have confirmed for the very first time the specific immune memor...

'Precision Medicine' may not always be so precise

Precision Medicine in oncology, where genetic testing is used to determine the best drugs to treat cancer patients, is not always so precise when applied to some of the w...

Novartis announces the planned acquisition of Adva…

Novartis announced today, that it has entered a memorandum of understanding with Advanced Accelerator Applications (AAA) under which Novartis intends to commence a tender...

New tissue-engineered blood vessel replacements on…

Researchers at the University of Minnesota have created a new lab-grown blood vessel replacement that is composed completely of biological materials, but surprisingly doe...

China's out of control 'silent killer' affects one…

More than one-third of adults in China have high blood pressure - often dubbed the "silent killer" for its lack of symptoms - but only about one in 20 have the condition ...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]